These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 21771617)

  • 1. Integrin binding human antibody constant domains--probing the C-terminal structural loops for grafting the RGD motif.
    Traxlmayr MW; Wozniak-Knopp G; Antes B; Stadlmayr G; Rüker F; Obinger C
    J Biotechnol; 2011 Sep; 155(2):193-202. PubMed ID: 21771617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells.
    Wright A; Morrison SL
    J Immunol; 1998 Apr; 160(7):3393-402. PubMed ID: 9531299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
    Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
    J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of IgG(1) variants with increased affinity to FcγRIIIa and unaltered affinity to FcγRI and FcRn: comparison of soluble receptor-based and cell-based binding assays.
    Lu Y; Vernes JM; Chiang N; Ou Q; Ding J; Adams C; Hong K; Truong BT; Ng D; Shen A; Nakamura G; Gong Q; Presta LG; Beresini M; Kelley B; Lowman H; Wong WL; Meng YG
    J Immunol Methods; 2011 Feb; 365(1-2):132-41. PubMed ID: 21185301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Fc binding site for streptococcal protein G is in the C gamma 2-C gamma 3 interface region of IgG and is related to the sites that bind staphylococcal protein A and human rheumatoid factors.
    Stone GC; Sjöbring U; Björck L; Sjöquist J; Barber CV; Nardella FA
    J Immunol; 1989 Jul; 143(2):565-70. PubMed ID: 2738404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding of divalent H-2Kd/IgG2aFc fusion protein to murine macrophage via Fc-FcR interaction.
    Xiao W; Chen X; Lin Zhou ; Lu S; Liang Z; Wu X
    Cell Mol Immunol; 2007 Apr; 4(2):147-51. PubMed ID: 17571461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A C-terminal interdomain disulfide bond significantly stabilizes the Fc fragment of IgG.
    Wozniak-Knopp G; Rüker F
    Arch Biochem Biophys; 2012 Oct; 526(2):181-7. PubMed ID: 22483683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Field flow fractionation for assessing neonatal Fc receptor and Fcγ receptor binding to monoclonal antibodies in solution.
    Pollastrini J; Dillon TM; Bondarenko P; Chou RY
    Anal Biochem; 2011 Jul; 414(1):88-98. PubMed ID: 21385563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of methionine oxidation on the binding of human IgG1 to Fc Rn and Fc gamma receptors.
    Bertolotti-Ciarlet A; Wang W; Lownes R; Pristatsky P; Fang Y; McKelvey T; Li Y; Li Y; Drummond J; Prueksaritanont T; Vlasak J
    Mol Immunol; 2009 May; 46(8-9):1878-82. PubMed ID: 19269032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fc Engineering: Tailored Synthetic Human IgG1-Fc Repertoire for High-Affinity Interaction with FcRn at pH 6.0.
    Saxena A; Bai B; Hou SC; Jiang L; Ying T; Miersch S; Sidhu SS; Wu D
    Methods Mol Biol; 2018; 1827():399-417. PubMed ID: 30196509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methods to engineer and identify IgG1 variants with improved FcRn binding or effector function.
    Kelley RF; Meng YG
    Methods Mol Biol; 2012; 901():277-93. PubMed ID: 22723108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural requirements of immunoglobulin G for binding to the Fc gamma receptors of the human tumor cell lines U937, HL-60, ML-1, and K562.
    McCool D; Birshtein BK; Painter RH
    J Immunol; 1985 Sep; 135(3):1975-80. PubMed ID: 3860563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
    Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
    Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions.
    Grevys A; Bern M; Foss S; Bratlie DB; Moen A; Gunnarsen KS; Aase A; Michaelsen TE; Sandlie I; Andersen JT
    J Immunol; 2015 Jun; 194(11):5497-508. PubMed ID: 25904551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding.
    Morgan A; Jones ND; Nesbitt AM; Chaplin L; Bodmer MW; Emtage JS
    Immunology; 1995 Oct; 86(2):319-24. PubMed ID: 7490135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural characterization of a human Fc fragment engineered for extended serum half-life.
    Oganesyan V; Damschroder MM; Woods RM; Cook KE; Wu H; Dall'acqua WF
    Mol Immunol; 2009 May; 46(8-9):1750-5. PubMed ID: 19250681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hybrid IgA2/IgG1 antibodies with tailor-made effector functions.
    Chintalacharuvu KR; Vuong LU; Loi LA; Larrick JW; Morrison SL
    Clin Immunol; 2001 Oct; 101(1):21-31. PubMed ID: 11580223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspects of the molecular structure of IgG subclasses.
    Burton DR; Gregory L; Jefferis R
    Monogr Allergy; 1986; 19():7-35. PubMed ID: 2945094
    [No Abstract]   [Full Text] [Related]  

  • 19. Human IgG1 Cgamma1 domain is crucial for the bioactivity of the engineered anti-CD20 antibodies.
    Geng S; Feng J; Li Y; Kang X; Sun Y; Gu X; Huang Y; Chang H; Shen BF
    Cell Mol Immunol; 2007 Apr; 4(2):121-5. PubMed ID: 17484806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates.
    Datta-Mannan A; Witcher DR; Tang Y; Watkins J; Jiang W; Wroblewski VJ
    Drug Metab Dispos; 2007 Jan; 35(1):86-94. PubMed ID: 17050651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.